FDA approves stand-alone 3D screening with Siemens Tomosynthesis Platform

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Siemens Healthineers has received the approval of the FDA in the use of their Mammomat Inspiration with Tomosynthesis Option, the first and only digital mammography system to use a 3D digital breast tomosynthesis (DBT) platform as a stand-alone screening and diagnostic system.

Currently, all other mammography systems on the market require a combination of 2D and 3D examinations. The FDA approval of the 3D-only application was supported by a study that resulted in radiologists decreased average recall rates by an average of 19 percent without the need for a 2D image by demonstrating their ability to increase cancer detection at a lower radiation dose than combined 2D and DBT.

“Siemens is proud to announce the availability of 3D-only screening with our Mammomat Inspiration with Tomosynthesis Option digital mammography system,” said Martin Silverman, Vice President of X-ray Products at Siemens Healthineers. “Although this is the first breast tomosynthesis solution on the market to demonstrate statistically superior results to 2D as a stand-alone breast exam, we know many providers will continue using 3D tomosynthesis as an adjunct to 2D screenings. Those providers who use our platform, however, will do so with confidence, knowing our 3D is a proven stand-alone option.”